Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Schizophrenia

Free Subscription Articles published in Neuropsychopharmacology Retrieve available abstracts of 45 articles: HTML format Text format

Single Articles

January 2012
1. SWERDLOW NR
   Beyond Antipsychotics: Pharmacologically-Augmented Cognitive Therapies (PACTs) for Schizophrenia.
   Neuropsychopharmacology. 2012;37:310-1.
   PubMed     Text format     Related articles   
   
   
   
   
2. FEIFEL D
   Oxytocin as a potential therapeutic target for schizophrenia and other neuropsychiatric conditions.
   Neuropsychopharmacology. 2012;37:304-5.
   PubMed     Text format     Related articles   
   
   
   
   December 2011
3. BRUNZELL DH , McIntosh JM
   Alpha7 Nicotinic Acetylcholine Receptors Modulate Motivation to Self-Administer Nicotine: Implications for Smoking and Schizophrenia.
   Neuropsychopharmacology. 2011 Dec 14. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2011
4. GASTAMBIDE F , Cotel MC, Gilmour G, O'Neill MJ, et al
   Selective Remediation of Reversal Learning Deficits in the Neurodevelopmental MAM Model of Schizophrenia by a Novel mGlu5 Positive Allosteric Modulator.
   Neuropsychopharmacology. 2011 Nov 30. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. MATRISCIANO F , Tueting P, Maccari S, Nicoletti F, et al
   Pharmacological Activation of Group-II Metabotropic Glutamate Receptors Corrects a Schizophrenia-Like Phenotype Induced by Prenatal Stress in Mice.
   Neuropsychopharmacology. 2011 Nov 16. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. FUNK AJ , McCullumsmith RE, Haroutunian V, Meador-Woodruff JH, et al
   Abnormal Activity of the MAPK- and cAMP-Associated Signaling Pathways in Frontal Cortical Areas in Postmortem Brain in Schizophrenia.
   Neuropsychopharmacology. 2011 Nov 2. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. SHIM JC , Jung DU, Jung SS, Seo YS, et al
   Adjunctive Varenicline Treatment with Antipsychotic Medications for Cognitive Impairments in People with Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial.
   Neuropsychopharmacology. 2011 Nov 2. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. GAVIN DP , Sharma RP, Chase KA, Matrisciano F, et al
   Growth Arrest and DNA-Damage-Inducible, Beta (GADD45b)-Mediated DNA Demethylation in Major Psychosis.
   Neuropsychopharmacology. 2011 Nov 2. doi: 10.1038/npp.2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. FATEMI SH
   Reelin, a marker of stress resilience in depression and psychosis.
   Neuropsychopharmacology. 2011;36:2371-2.
   PubMed     Text format     Related articles   
   
   
   
   October 2011
10. ZHANG Q , Shen Q, Xu Z, Chen M, et al
    The Effects of CACNA1C Gene Polymorphism on Spatial Working Memory in Both Healthy Controls and Patients with Schizophrenia or Bipolar Disorder.
    Neuropsychopharmacology. 2011 Oct 19. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. ROUSSOS P , Giakoumaki SG, Adamaki E, Anastasios G, et al
    The association of schizophrenia risk d-amino Acid oxidase polymorphisms with sensorimotor gating, working memory and personality in healthy males.
    Neuropsychopharmacology. 2011;36:2370.
    PubMed     Text format     Related articles   
    
    
    
    
12. COHEN D , De Hert M
    Endogenic and Iatrogenic Diabetes Mellitus in Drug-naive Schizophrenia: The Role of Olanzapine and its Place in the Psychopharmacological Treatment Algorithm.
    Neuropsychopharmacology. 2011;36:2368-9.
    PubMed     Text format     Related articles   
    
    
    
    September 2011
13. MOGHADDAM B , Javitt D
    From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment.
    Neuropsychopharmacology. 2011 Sep 28. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. JONES CK , Byun N, Bubser M
    Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia.
    Neuropsychopharmacology. 2011 Sep 28. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. MARENCO S , Stein JL, Savostyanova AA, Sambataro F, et al
    Investigation of Anatomical Thalamo-Cortical Connectivity and fMRI Activation in Schizophrenia.
    Neuropsychopharmacology. 2011 Sep 28. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. FRIEDMAN JI , Lindenmayer JP, Alcantara F, Bowler S, et al
    Pimozide augmentation of clozapine inpatients with schizophrenia and schizoaffective disorder unresponsive to clozapine monotherapy.
    Neuropsychopharmacology. 2011;36:2150.
    PubMed     Text format     Related articles   
    
    
    
    August 2011
17. BROOKS JM , Sarter M, Bruno JP
    Transient Inactivation of the Neonatal Ventral Hippocampus Permanently Disrupts the Mesolimbic Regulation of Prefrontal Cholinergic Transmission: Implications for Schizophrenia.
    Neuropsychopharmacology. 2011 Aug 3. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. TEIXEIRA CM , Martin ED, Sahun I, Masachs N, et al
    Overexpression of Reelin Prevents the Manifestation of Behavioral Phenotypes Related to Schizophrenia and Bipolar Disorder.
    Neuropsychopharmacology. 2011 Aug 3. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. LAHTI AC , Reid MA
    Is there Evidence for Neurotoxicity in the Prodromal and Early Stages of Schizophrenia?
    Neuropsychopharmacology. 2011;36:1779-80.
    PubMed     Text format     Related articles   
    
    
    
    June 2011
20. GLAUSIER JR , Lewis DA
    Selective Pyramidal Cell Reduction of GABA(A) Receptor alpha1 Subunit Messenger RNA Expression in Schizophrenia.
    Neuropsychopharmacology. 2011 Jun 15. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. CHAI XJ , Whitfield-Gabrieli S, Shinn AK, Gabrieli JD, et al
    Abnormal Medial Prefrontal Cortex Resting-State Connectivity in Bipolar Disorder and Schizophrenia.
    Neuropsychopharmacology. 2011 Jun 8. doi: 10.1038/npp.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
22. HASHIMOTO R , Ohi K, Yasuda Y, Fukumoto M, et al
    Variants of the RELA Gene are Associated with Schizophrenia and their Startle Responses.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. GILL KM , Lodge DJ, Cook JM, Aras S, et al
    A Novel alpha5GABA(A)R-Positive Allosteric Modulator Reverses Hyperactivation of the Dopamine System in the MAM Model of Schizophrenia.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. FRIEDMAN JI , Lindenmayer JP, Alcantara F, Bowler S, et al
    Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy.
    Neuropsychopharmacology. 2011;36:1317.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
25. VOINESKOS AN , Lerch JP, Felsky D, Tiwari A, et al
    The ZNF804A Gene: Characterization of a Novel Neural Risk Mechanism for the Major Psychoses.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
26. SCHULTZ CC , Nenadic I, Koch K, Wagner G, et al
    Reduced Cortical Thickness is Associated with the Glutamatergic Regulatory Gene Risk Variant DAOA Arg30Lys in Schizophrenia.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. FUENTE-SANDOVAL CD , Leon-Ortiz P, Favila R, Stephano S, et al
    Higher Levels of Glutamate in the Associative-Striatum of Subjects with Prodromal Symptoms of Schizophrenia and Patients with First-Episode Psychosis.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. PAINE TA , Slipp LE, Carlezon WA Jr
    Schizophrenia-Like Attentional Deficits Following Blockade of Prefrontal Cortex GABA(A) Receptors.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. ROUSSOS P , Giakoumaki SG, Adamaki E, Anastasios G, et al
    The Association of Schizophrenia Risk D-Amino Acid Oxidase Polymorphisms With Sensorimotor Gating, Working Memory and Personality in Healthy Males.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. DALTON VS , Long LE, Weickert CS, Zavitsanou K, et al
    Paranoid Schizophrenia is Characterized by Increased CB(1) Receptor Binding in the Dorsolateral Prefrontal Cortex.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
31. ORTEGA-ALVARO A , Aracil-Fernandez A, Garcia-Gutierrez MS, Navarrete F, et al
    Deletion of CB(2) Cannabinoid Receptor Induces Schizophrenia-Related Behaviors in Mice.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
32. FRIEDMAN JI , Lindenmayer JP, Alcantara F, Bowler S, et al
    Pimozide Augmentation of Clozapine Inpatients with Schizophrenia and Schizoaffective Disorder Unresponsive to Clozapine Monotherapy.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
33. KATSEL P , Byne W, Roussos P, Tan W, et al
    Astrocyte and Glutamate Markers in the Superficial, Deep, and White Matter Layers of the Anterior Cingulate Gyrus in Schizophrenia.
    Neuropsychopharmacology. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. KEEFE RS , Kraus MS, Krishnan RR
    Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.
    Neuropsychopharmacology. 2011;36:367-8.
    PubMed     Text format     Related articles   
    
    
    
    November 2010
35. MCCLAY JL , Adkins DE, Aberg K, Bukszar J, et al
    Genome-Wide Pharmacogenomic Study of Neurocognition As an Indicator of Antipsychotic Treatment Response in Schizophrenia.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. GAEBEL W , Schreiner A, Bergmans P, Arce RD, et al
    Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
37. AHN K , Gil R, Seibyl J, Sewell RA, et al
    Probing GABA Receptor Function in Schizophrenia with Iomazenil.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
38. CORLETT PR , Honey GD, Krystal JH, Fletcher PC, et al
    Glutamatergic Model Psychoses: Prediction Error, Learning, and Inference.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. LESH TA , Niendam TA, Minzenberg MJ, Carter CS, et al
    Cognitive Control Deficits in Schizophrenia: Mechanisms and Meaning.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. MINZENBERG MJ , Firl AJ, Yoon JH, Gomes GC, et al
    Gamma Oscillatory Power is Impaired During Cognitive Control Independent of Medication Status in First-Episode Schizophrenia.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
41. BITANIHIRWE BK , Peleg-Raibstein D, Mouttet F, Feldon J, et al
    Late Prenatal Immune Activation in Mice Leads to Behavioral and Neurochemical Abnormalities Relevant to the Negative Symptoms of Schizophrenia.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. WALTZ JA , Schweitzer JB, Ross TJ, Kurup PK, et al
    Abnormal Responses to Monetary Outcomes in Cortex, but not in the Basal Ganglia, in Schizophrenia.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. GAEBEL W , Schreiner A, Bergmans P, de Arce R, et al
    Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
44. WEINER E , Conley RR, Ball MP, Feldman S, et al
    Adjunctive Risperidone for Partially Responsive People with Schizophrenia Treated with Clozapine.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. LENCZ T , Szeszko PR, Derosse P, Burdick KE, et al
    A Schizophrenia Risk Gene, ZNF804A, Influences Neuroanatomical and Neurocognitive Phenotypes.
    Neuropsychopharmacology. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: